S
Sarah Nikiforow
Researcher at Harvard University
Publications - 169
Citations - 6379
Sarah Nikiforow is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 31, co-authored 134 publications receiving 4414 citations. Previous affiliations of Sarah Nikiforow include Brigham and Women's Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
John H. Stone,Matthew J. Frigault,Naomi Serling-Boyd,Ana D. Fernandes,Liam Harvey,Andrea S. Foulkes,Nora Horick,Brian C. Healy,Ruta Shah,Ana Maria Bensaci,Ann E. Woolley,Sarah Nikiforow,Nina Lin,Manish Sagar,Harry M Schrager,David S. Huckins,Matthew Axelrod,Michael D. Pincus,Jorge Fleisher,Chana A. Sacks,Michael Dougan,Crystal M. North,Yuan Di C. Halvorsen,Tara K. Thurber,Zeina Dagher,Allison K. Scherer,Rachel Wallwork,Arthur Y. Kim,Sara R. Schoenfeld,Pritha Sen,Tomas G. Neilan,Cory A. Perugino,Sebastian Unizony,Deborah S. Collier,Mark Matza,Janeth Yinh,Kathryn Bowman,Eric A. Meyerowitz,Amna Zafar,Zsofia D. Drobni,Marcy B. Bolster,Minna J. Kohler,Kristin M. D’Silva,Jonathan Dau,Megan Lockwood,Caroline Cubbison,Brittany Weber,Michael K. Mansour +47 more
TL;DR: Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19, and some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide.
Journal ArticleDOI
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki,Jussi Koivunen,Atsuko Ogino,Masahiko Yanagita,Sarah Nikiforow,Wei Zheng,Christopher S. Lathan,J. Paul Marcoux,Jinyan Du,Katsuhiro Okuda,Marzia Capelletti,Takeshi Shimamura,Dalia Ercan,Magda Stumpfova,Yun Xiao,Stanislawa Weremowicz,Mohit Butaney,Stephanie Heon,Keith D. Wilner,James G. Christensen,Michael J. Eck,Kwok-Kin Wong,Neal I. Lindeman,Nathanael S. Gray,Scott J. Rodig,Pasi A. Jänne +25 more
TL;DR: Two mechanisms of ALK TKI resistance identified from a crizotinib-treated non-small cell lung cancer (NSCLC) patient and in a cell line generated from the resistant tumor (DFCI076) as well as from studying a resistant version of the ALk TKI (TAE684)-sensitive H3122 cell line.
Journal ArticleDOI
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Christopher J. Gibson,R. Coleman Lindsley,Vatche Tchekmedyian,Brenton G. Mar,Jiantao Shi,Siddhartha Jaiswal,Alysia Bosworth,Liton Francisco,Jianbo He,Anita Bansal,Elizabeth A. Morgan,Ann S. LaCasce,Arnold S. Freedman,David C. Fisher,Eric D. Jacobsen,Philippe Armand,Edwin P. Alyea,John Koreth,Vincent T. Ho,Robert J. Soiffer,Joseph H. Antin,Jerome Ritz,Sarah Nikiforow,Stephen J. Forman,Franziska Michor,Donna Neuberg,Ravi Bhatia,Smita Bhatia,Benjamin L. Ebert +28 more
TL;DR: In patients undergoing ASCT for lymphoma, CHIP at the time of transplantation is associated with inferior survival and increased risk of TMN, and targeted sequencing on cryopreserved aliquots of autologous stem-cell products showed that patients with CHIP had significantly inferior overall survival compared with those without it.
Journal ArticleDOI
Kaposi's Sarcoma-Associated Herpesvirus Open Reading Frame 50/Rta Protein Activates the Entire Viral Lytic Cycle in the HH-B2 Primary Effusion Lymphoma Cell Line
L Gradoville,Jennifer Gerlach,Elizabeth Grogan,Duane Shedd,Sarah Nikiforow,Craig Metroka,George Miller +6 more
TL;DR: Introducing an ORF50 expression plasmid is sufficient to drive the lytic cycle to completion in cultured PEL cells and is competent to initiate the entire viral lytic life cycle including lytic viral DNA replication, late-gene expression with appropriate kinetics, and virus release.
Journal ArticleDOI
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Marcelo C. Pasquini,Zhen-Huan Hu,Kevin J. Curran,Theodore W. Laetsch,Frederick L. Locke,Rayne H. Rouce,Michael A. Pulsipher,Christine L Phillips,Amy K. Keating,Matthew J. Frigault,Dana Salzberg,Samantha Jaglowski,Joshua P. Sasine,Joseph Rosenthal,Monalisa Ghosh,Daniel J. Landsburg,Steven P. Margossian,Paul L. Martin,Manali Kamdar,Peiman Hematti,Sarah Nikiforow,Cameron J. Turtle,Miguel-Angel Perales,Patricia Steinert,Mary M. Horowitz,Amy Moskop,Lida Bubuteishvili Pacaud,Lan Yi,Raghav Chawla,Eric Bleickardt,Stephan A. Grupp,Stephan A. Grupp +31 more
TL;DR: This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.